CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-06-30): Peptide vaccine shows some promise in hard-to-treat HCV

Drug & Device Development

Peptide vaccine shows some promise in hard-to-treat HCV

Last Updated: 2008-06-30 15:20:51 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The synthetic peptide vaccine IC41 induces a T-cell response specific to hepatitis C virus (HCV) in patients with chronic HCV infection refractory to standard therapy, German researchers report.

"This clinical study with the HCV therapeutic vaccine IC41clearly shows that a T lymphocyte immune response can be induced in the difficult-to-treat non-responders to previous interferon-based HCV therapies," lead investigator Dr. Michael P. Manns told Reuters Health.

In the May issue of Gastroenterology, Dr. Manns of Hannover Medical School and colleagues note that in an earlier study with healthy volunteers the vaccine was shown to be safe and capable of eliciting HCV-specific immune response.

In the current trial, the team studied 60 patients with chronic HCV infection who were not responding or were relapsing on standard therapy. The patients were randomized into five groups. Three groups received one of three doses of a total of six IC41 vaccinations; a fourth group received HCV peptides alone (control group); and a fifth group received the poly-L-arginine adjuvant alone (control group).

The researchers detected T-cell proliferation in 67% of patients who received the vaccine compared with 17% in those who received the HCV peptides alone. No response was seen in patients who received the adjuvant alone.

Three patients had a plasma HCV RNA response; all were in one of the two highest dose vaccine groups. These patients had a greater than 1 log decline in HCV RNA. However, this was transient and was followed by a rebound to baseline levels.

Nevertheless, concluded Dr. Manns, "although the decrease in viral load is minor, the stimulation of the cellular immune response against important HCV T lymphocytes is encouraging."

In an accompanying editorial, Dr. Carlo Ferrari of Azienda Ospedaliero-Universitaria di Parma, Italy, observes: "Although definitive answers are still lacking, what is promising for immunotherapy is that our knowledge of the complex mechanisms governing T-cell differentiation and influencing T-cell dysfunction in chronic hepatitis C are rapidly improving."

Gastroenterology 2008;134:1385-1395,1601-1614.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.